CD19 and lymphoma: However, when treated with Apt-Dox, the drug was mainly taken up by CD19-positive lymphoma cells (Figure 7, the lower panel), suggesting that Apt-Dox could differentiate CD19-positive cells from CD19-negative cells and selectively deliver Dox into the former.